Anavex Lf SC AVXL

$1.82 -0.07 (-3.70%)

Valuation

Market cap
175,197,000
Revenue TTM
$0
Net income TTM
$-46,380,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,989,000
Avg volume
931,328
Day's range
$1.72 – $1.88
Shares out
92,697,000
Stochastic %K
13%
Beta
1.17
Analysts
Sell
Price target
$20.00

Price

Company profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase...

Show more

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
844 689 3939
Website
https://www.anavex.com
Address
630 5th Avenue, 20th Floor, New York, United States

Latest news

Stocktwits

papatrick Oct 3, 10:55 PM
$AVXL Thanks so much for those explanations, i will sleep better cause Skarpelos and Missling were buddies, controlling everything, using the rest of the board as dummys
0 replies
Silo46 Oct 3, 10:25 PM
$AVXL anybody here with me since 2016?
0 replies
papatrick Oct 3, 11:27 AM
$AVXL someone told me that Skarpelos died last year, apparently it is not true, and he still own more than 1 M shares and one of the director at Avxl, i dont see anything telling the reverse. He is the founder, he bought the patents, he hired the firsts CEOs, particularly Missling in 2013. He probably is the real control of the company somehow...should be around 63 years old...somehow his seat of director is hidden behind the BOD
1 replies
AGB2G Oct 2, 10:10 PM
$AVXL I did a deep dive into Anavex’s steep price decline, this is what I found. This sudden drop is tied to official events, most notably: 1.) The recent Wave of Class Action Lawsuits: On 9/30 and 10/1, multiple prominent law firms filed class action lawsuits against Anavex. 2.) These lawsuits are based on the company's own prior SEC filings. They point directly to Anavex’s admission of "material weaknesses in internal control over financial reporting” and the fallout surrounding the termination of Missling for cause earlier this year. 3.) The termination of C.M. on April 30th was for conduct "inconsistent with Company Policy," a development the lawsuits claim was hidden until subsequent delayed regulatory filings forced the disclosure, harming shareholders. 4.) Seizing on these lawsuits, off-exchange short selling for Anavex has turned highly aggressive — all thanks to the misdeeds of Christoper Missling. I believe in the science, I am long Anavex, and I ain’t selling one share!
1 replies
Trainguy1 Oct 2, 9:52 PM
$AVXL Here’s a short video about the current state of human understanding of Alzheimer’s disease and current treatments. I think many of you will like it. Professor Dave makes a wide variety of science videos. He has also produced a line of debunking videos, which pay his bills. https://youtu.be/ml8XMhB3DKY?is=7WVR18-GbG-mvDT8
0 replies
autophagy1 Oct 2, 8:48 PM
$AVXL Another poster tells all about o Re: georgejjl post# 521339 Wednesday, September 30, 2026 1:30:59 PM For over ten years you've been pushing the same endless pump on AVXL, wrapping it in "GOD bless" like it somehow makes the stock holy. It doesn't. God knows exactly what you're doing. Newcomers don't know the history. They just see your cheerful pumping volume posts and think they're getting the truth. Some of them will buy because of your sweet talk. That's on you. I remember you from the first big drop ten years ago, when the stock crashed from $14 to $3 in a couple of days. You bragged about selling before the bottom while people who listened to your earlier "GOD bless" recruitment got wrecked. Everyone was pissed. Then you went quiet for months until the heat died down. Once people forgot, you came back and started the exact same routine. Look at the record. What you said vs. reality. From the IPO in the $5 range to today—more than 50% down after a decade—and you're still pumping like !
1 replies
Alex1710 Oct 2, 7:51 PM
$AVXL If a drug were to be develop to bring back sens to people all of you here should be enrolled.😁
0 replies
papatrick Oct 2, 7:41 PM
$AVXL let see if Missling can keep it low till the close....the Anti-Chris
0 replies